John Catalano

Adj ClinAssProf

If you made any changes in Pure these will be visible here soon.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1998 2018

Phase Ib study of the mTOR inhibitor everolimus with low dose cytarabine in elderly acute myeloid leukemia

Tiong, I. S., Tan, P., McManus, J., Cummings, N., Sadawarte, S., Catalano, J., Hills, R. & Wei, A., 2018, In : Leukemia and Lymphoma. 59, 2, p. 493-496 4 p.

Research output: Contribution to journalLetterResearchpeer-review

52 Citations (Scopus)

Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

Thieblemont, C., Tilly, H., Da Silva, M. G., Casasnovas, R. O., Fruchart, C., Morschhauser, F., Haioun, C., Lazarovici, J., Grosicka, A., Perrot, A., Trotman, J., Sebban, C., Caballero, D., Greil, R., Van Eygen, K., Cohen, A. M., Gonzalez, H., Bouabdallah, R., Oberic, L., Corront, B. & 10 others, Choufi, B., Lopez-Guillermo, A., Catalano, J., Van Hoof, A., Briere, J., Cabeçadas, J., Salles, G., Gaulard, P., Bosly, A. & Coiffier, B. B., 1 Aug 2017, In : Journal of Clinical Oncology. 35, 22, p. 2473-2481 9 p.

Research output: Contribution to journalArticleResearchpeer-review

72 Citations (Scopus)

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

Verstovsek, S., Mesa, R. A., Gotlib, J. R., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M. W. N., Miller, C. B., Silver, R. T., Talpaz, M., Winton, E. F., Harvey, J. H., Arcasoy, M. O., Hexner, E. O., Lyons, R. M., Paquette, R. L., Raza, A., Jones, M., Kornacki, D., Sun, K. & 1 others, Kantarjian, H. M., 22 Feb 2017, In : Journal of Hematology & Oncology. 10, 1, p. 1-14 14 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access

The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study

Tan, P., Tiong, I. S., Fleming, S., Pomilio, G., Cummings, N., Droogleever, M., McManus, J., Schwarer, A., Catalano, J., Patil, S., Avery, S., Spencer, A. & Wei, A., 2017, In : Oncotarget. 8, 32, p. 52269-52280 12 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access

Bortezomib-based antibody depletion for refractory autoimmune hematological diseases

Ratnasingam, S., Walker, P. A., Tran, H., Kaplan, Z. S., McFadyen, J., Tran, H., Teh, T-C., Fleming, S., Catalano, J. V., Chunilal, S. D., Johnston, A., Opat, S. S. & Shortt, J., 22 Nov 2016, In : Blood Advances. 1, 1, p. 31-35 5 p.

Research output: Contribution to journalArticleResearchpeer-review